Some content of this application is unavailable at the moment.
If this situation persist, please contact us atFeedback&Contact
1. (WO2018007615) VIRAL POLYPEPTIDE FRAGMENTS THAT BIND CELLULAR POL II C-TERMINAL DOMAIN (CTD) AND THEIR USES
Latest bibliographic data on file with the International BureauSubmit observation

Pub. No.: WO/2018/007615 International Application No.: PCT/EP2017/067144
Publication Date: 11.01.2018 International Filing Date: 07.07.2017
IPC:
C12N 9/12 (2006.01) ,G06F 19/16 (2011.01)
C CHEMISTRY; METALLURGY
12
BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
N
MICRO-ORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICRO-ORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
9
Enzymes, e.g. ligases (6.); Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating, or purifying enzymes
10
Transferases (2.)
12
transferring phosphorus containing groups, e.g. kinases (2.7)
G PHYSICS
06
COMPUTING; CALCULATING; COUNTING
F
ELECTRIC DIGITAL DATA PROCESSING
19
Digital computing or data processing equipment or methods, specially adapted for specific applications
10
Bioinformatics, i.e. methods or systems for genetic or protein-related data processing in computational molecular biology
16
for molecular structure, e.g. structure alignment, structural or functional relations, protein folding, domain topologies, drug targeting using structure data, involving two-dimensional or three-dimensional structures
Applicants:
THE EUROPEAN MOLECULAR BIOLOGY LABORATORY [DE/DE]; Meyerhofstr. 1 69117 Heidelberg, DE
Inventors:
CUSACK, Stephen; FR
PFLUG, Alexander; GB
LUKARSKA, Maria; FR
Agent:
ZWICKER, Jörk; DE
Priority Data:
16178396.407.07.2016EP
Title (EN) VIRAL POLYPEPTIDE FRAGMENTS THAT BIND CELLULAR POL II C-TERMINAL DOMAIN (CTD) AND THEIR USES
(FR) FRAGMENTS POLYPEPTIDIQUES VIRAUX QUI SE LIENT AU DOMAINE C-TERMINAL DE POL II CELLULAIRE (CTD) ET LEURS UTILISATIONS
Abstract:
(EN) The present invention relates to in silico methods for identifying compounds which decrease or prevent the binding of the viral RNA-dependent RNA polymerase from the Orthomyxoviridae family or variant thereof, to its ligand, (preferably to cellular Pol II, more preferably to CTD), as well as methods of producing the identified compounds. The present invention also relates to a compounds identifiable and/or producible by said methods. The present invention also relates to antibodies directed against the binding site of the RNA-dependent RNA polymerase, to its ligand (in particular to cellular Pol II, in particular to CTD of Pol II) as well as nucleic acids encoding said antibodies and vectors comprising the nucleic acid. The present invention relates to a pharmaceutical composition producible according to said method, and/or comprising said compound, said antibody, said nucleic acid, or said vector. The present invention also relates to the use of said compound, said antibody, said nucleic acid, said vector or said pharmaceutical in treating, ameliorating, or preventing disease conditions caused by viral infections with viruses of the Orthomyxoviridae family.
(FR) La présente invention concerne des procédés in silico pour identifier des composés qui réduisent ou empêchent la liaison de l'ARN-polymérase dépendant de l'ARN viral de la famille des Orthomyxoviridae ou d'un variant correspondant, à son ligand (de préférence au Pol II cellulaire, plus préférablement au CTD), ainsi que des procédés de production des composés identifiés. La présente invention concerne également des composés identifiables et/ou pouvant être produits par lesdits procédés. La présente invention concerne également des anticorps dirigés contre le site de liaison de l'ARN polymérase ARN-dépendante à son ligand (en particulier au Pol II cellulaire, en particulier le CTD de Pol II) ainsi que des acides nucléiques codant pour lesdits anticorps et des vecteurs comprenant l'acide nucléique. La présente invention concerne une composition pharmaceutique pouvant être produite selon ledit procédé et/ou comprenant ledit composé, ledit anticorps, ledit acide nucléique ou ledit vecteur. La présente invention concerne également l'utilisation dudit composé, dudit anticorps, dudit acide nucléique, dudit vecteur ou dudit produit pharmaceutique dans le traitement, l'amélioration ou la prévention d'états pathologiques provoqués par des infections virales par des virus de la famille des Orthomyxoviridae.
Designated States: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW
African Regional Intellectual Property Organization (ARIPO) (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW)
Eurasian Patent Organization (AM, AZ, BY, KG, KZ, RU, TJ, TM)
European Patent Office (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR)
African Intellectual Property Organization (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG)
Publication Language: English (EN)
Filing Language: English (EN)
Also published as:
AU2017294090CA3029784CN109477081EP3481946